UK markets open in 2 hours 48 minutes

Atossa Therapeutics, Inc. (ATOS)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.29000.0000 (0.00%)
At close: 04:00PM EDT
1.3100 +0.02 (+1.55%)
After hours: 07:19PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.2900
Open1.2900
Bid1.1800 x 800
Ask1.2100 x 800
Day's range1.2400 - 1.3399
52-week range0.5900 - 1.3900
Volume817,107
Avg. volume642,015
Market cap161.642M
Beta (5Y monthly)1.16
PE ratio (TTM)N/A
EPS (TTM)-0.2400
Earnings date20 Mar 2024 - 25 Mar 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est4.58
  • GlobeNewswire

    Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements

    SEATTLE, March 18, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that on March 15, 2024, the Company received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2). Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of si

  • GlobeNewswire

    Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors

    SEATTLE, March 12, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced that Tessa Cigler, M.D., M.P.H. was appointed to Atossa’s board of directors, effective immediately. Dr. Cigler is a medical oncologist and clinical investigator at the Weill Cornell Breast Center in New York

  • GlobeNewswire

    Data from Atossa’s Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting

    SEATTLE, March 06, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) announced today that data from the 40mg pharmacokinetic (PK) run-in cohort of the ongoing Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) study will be presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10, 2024, in San Diego, California. The EVANGELINE study is investigating (Z)-endoxifen as a neoadjuvant treatment for premenopausal women diagnosed w